Menu
ETF
Annual · values2025202420232022202120202019
Operating Cash Flow-15.26 M USD-12.69 M USD-11.95 M USD-19.59 M USD-15.73 M USD-5.68 M USD-5.34 M USD
Depreciation & Amortization1.31 M USD581000 USD621000 USD669000 USD733000 USD717865 USD751228 USD
Stock-Based Compensation661000 USD762000 USD1.11 M USD2.40 M USD2.66 M USD2.17 M USD1.99 M USD
Capital Expenditures2.34 M USD568000 USD803000 USD924000 USD2.40 M USD120252 USD175599 USD
Cash Flow from Investing-7.53 M USD-568000 USD-853000 USD-924000 USD-2.61 M USD-120252 USD86223 USD
Cash Flow from Financing18.56 M USD17.88 M USD10.92 M USD24.17 M USD23.54 M USD4.47 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-17.60 M USD-13.26 M USD-12.75 M USD-20.51 M USD-18.13 M USD-5.80 M USD-5.52 M USD

Vivos Therapeutics, Inc. is a medical technology company that concentrates on addressing sleep apnea through innovative treatment solutions. Primarily known for its proprietary systems and devices, the company offers a non-surgical approach designed to improve airway function and alleviate symptoms for patients suffering from obstructive sleep apnea (OSA), a common and often undiagnosed condition linked to various health issues. Operating at the intersection of medical devices and dental care, Vivos provides its solutions primarily to healthcare professionals, enabling them with tools and training necessary to effectively manage and treat sleep disorders. This focus on a non-invasive methodology has positioned Vivos as a notable player in the sleep disorder treatment market. Its approach not only aims to provide relief for individuals but also reduces dependency on traditional continuous positive airway pressure (CPAP) machines. Vivos Therapeutics plays a significant role in enhancing patient care within the healthcare sector by bridging the gap between dentistry and medicine, helping to raise awareness and offer alternative treatments for sleep-related breathing disorders.